Forschungszentrum Borstel

Borstel-Hohenraden, Germany

Forschungszentrum Borstel

Borstel-Hohenraden, Germany

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-1 | Award Amount: 7.78M | Year: 2012

Next generation sequencing (NGS) has fundamentally altered genomic research. New developments will bring NGS costs and performance down to an everybodys technology with extreme potential for ultra fast and accurate molecular typing and diagnostic as it provides the ultimate whole genome information. However, technical and bioinformatics constraints, restrict the application of NGS to few highly experienced laboratories. The goal of this project is the transition of NGS from a basic research tool to a highly efficient technology for pathogen typing and diagnostics on the EU level. This objective will be achieved by establishing a unique European consortium that brings together three SMEs leading in the fields of data to knowledge and NGS genome research with leading experts in clinical microbiology of three model pathogens of high European and worldwide importance (methicillin-resistant Staphylococcus aureus, Campylobacter spp., and M. tuberculosis complex. Particularly we will i) develop bio-informatics pipelines for quality-controlled and easy interpretation of NGS data, ii) optimize sample preparation steps and evaluate newest NGS (Ion Torrent) and Optical Mapping (OM) technologies, and iii) develop new, dedicated NGS-based pathogen diagnostic kits. Ultimate goal is to generate automatically plain language reports and to implement GIS and space-time cluster detections for automatic early-warning systems based on NGS-data. Application programming interfaces and a microbial typing ontology for a linked web will be developed. Product-like prototypic software development for automatic analysis of microbial NGS-data will be guided by two leading SMEs. The development of new and improved tools/technologies in this SME-targeted project will overcome existing obstacles of NGS and open the door for a wide application of NGS for European scientists and clinical microbiologist, thus fostering competitiveness of Europe in NGS research and medical applications.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.2-2 | Award Amount: 13.07M | Year: 2014

Increase in antibiotic resistance is a global concern worldwide. The project NAREBs main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients. NAREB will address the problem of drug bioavailability inside the infected macrophages, transport across the bacterial cell wall, and avoidance of escape mechanisms (expressed by the pathogen). The success of the utilization of nanoparticles in the improvement of drug targeting in other diseases opens the way for novel applications in nanotechnology-based treatments aimed at controlling MDR-TB and MRSA. Specific objectives to achieve the main goal are: (i) Screening of different combinations of antibiotic drugs (small chemical molecules and/or biomacromolecules - glycopeptides) with nanocarriers (lipid, polymeric, biopolymeric); (ii) Loading of Transcription Factor Decoys (TFDs) designed to block the expression of essential bacterial genes in compatible nanoparticle systems and their testing as novel antibacterials; (iii) In vitro and in vivo testing of the best therapeutic combinations in relevant experimental models and using innovative bioimaging; (iv) Improved formulations of multifunctional particles containing selected antibiotics and TFDs for increasing the bioavailability of active molecules in the site of infection (targeting strategy, adapted route of administration) (v) Assessing safety, regulatory and production (GLP/GMP) aspects in relation with the most promising nanoformulations; (vi) Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations. The project NAREB brings together 15 partners (including 4 SMEs and 1 industry) from 8 EU Member and Associated States with outstanding complementary expertise, ranging from material engineering to molecular biology, pharmacology and medicine.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2010.2.3.3-1 | Award Amount: 16.37M | Year: 2011

To address the call for proposals Biology and control of vector-borne infections in Europe launched by the European Commission, we want to investigate the biological, ecological and epidemiological components of vector-borne diseases (VBD) introduction, emergence and spread, and to propose innovative tools for controlling them, building on the basis of acquired knowledge. We have selected the main groups of arthropod vectors involved in the transmission of vector-borne diseases in Europe: ticks, mosquitoes, sandflies, and biting midges (Culicoides). We have also selected the main diseases of actual or possible importance in human and veterinary public health. Rodents, insectivores and rodent-borne diseases have also been considered, both for their direct importance in public health, and for the major role of rodents and insectivores as reservoir hosts of many pathogens. We have put a strong focus on vector- and disease-quantitative modelling. The resulting predictive models will be used to assess climate or environmental change scenarios, as well as vector or disease control strategies. Human behaviour and risk perception are an important component of VBD introduction, emergence and spread. The consequences triggered by VBD for human and veterinary public health in Europe are just starting to emerge in public awareness. We will also account for this aspect of human and veterinary public health in our proposal. Finally, the set of innovative research methods, tools and results obtained during the project will be a step forward a generic approach of VBD in terms of disease monitoring and early warning systems, and will reinforce the general framework for an integrated pest and disease management system. For all these aspects, we will benefit from, and amplify the strong scientific results, capacity building, and research networks established by EDEN project on emerging, vector-borne diseases in a changing European environment.


Patent
Universitaetsklinikum Freiburg and Forschungszentrum Borstel | Date: 2013-03-04

The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.


Patent
Protectimmun GmbH and Forschungszentrum Borstel | Date: 2016-06-20

A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.


Patent
Forschungszentrum Borstel and Protectimmun GmbH | Date: 2013-10-21

A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 5.82M | Year: 2017

Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to: a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of -lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best -lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.


Patent
Forschungszentrum Borstel | Date: 2013-10-02

The present invention relates to new enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.


The present invention relates to a rhamno-polysaccharide antigen from Enterococcus faecium clonal complex which is useful as a vaccine component for therapy and/or prophylaxis of bacterial infection.


Patent
Forschungszentrum Borstel | Date: 2016-03-30

The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan Entamoeba histolytica. The compounds have been found to be useful for enhancing and/or inducing an immune response in a subject in need thereof. Specifically, the compounds have been found to be useful for the treatment of cancer diseases, such as breast cancer, and parasitic diseases, such as leishmaniasis. The invention also provides pharmaceutical compositions comprising the novel compounds.

Loading Forschungszentrum Borstel collaborators
Loading Forschungszentrum Borstel collaborators